Results 11 to 20 of about 29,286 (231)

Dasatinib-Related Chylothorax

Turkish Journal of Hematology, 2015
Dasatinib is a potent second-generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The most common adverse event associated with dasatinib therapy is fluid retention, including pleural effusion. Dasatinib-related chylothorax
Yen Min Huang, Cheng Hsu Wang, Jen Seng Huang, Kun Yun Yeh, Chien Hong Lai, Tsung Han Wu, Pei Hung Chang, Yueh Shih Chang, Yii Jenq Lan   +8 more
doaj   +2 more sources

Dasatinib-Induced Pulmonary Arterial Hypertension Treated with Upfront Combination Therapy

Case Reports in Cardiology, 2018
Pulmonary arterial hypertension (PAH) is a rare complication of dasatinib that was approved as a first-line therapy for chronic myelocytic leukemia (CML). A 24-year-old man presenting dyspnea at rest and leg edema was admitted to our hospital.
Makoto Nishimori, Tomoyuki Honjo, Kenji Kaihotsu, Naohiko Sone, Sachiko Yoshikawa, Junichi Imanishi, Kazuhiko Nakayama, Noriaki Emoto, Masanori Iwahashi   +8 more
doaj   +2 more sources

Dasatinib-induced hemorrhagic colitis complicated with cytomegalovirus infection

Hematology Reports, 2017
A 69-year-old man with chronic-phase chronic myeloid leukemia was initially treated with 100 mg dasatinib once a day. Despite a major molecular response within 9 months, he developed hemorrhagic colitis 32 months after starting dasatinib.
Aya Nakaya, Yoshiko Azuma, Shinya Fujita, Atsushi Satake, Takahisa Nakanishi, Yukie Tsubokura, Akiko Konishi, Masaaki Hotta, Hideaki Yoshimura, Kazuyoshi Ishii, Tomoki Ito, Shosaku Nomura   +11 more
doaj   +2 more sources

A strange cause of chylothorax- Dasatinib induced

Journal of Association of Pulmonologist of Tamil Nadu, 2018
Dasatinib is a potent second-generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. Pulmonary side effects like pleural effusion due fluid retention are common.
M Natraj, Dhanasekar, Irfan Ismail Ayub, Abdul Majeed Arshad, Rajagopalan, T Chandrasekar   +5 more
doaj   +1 more source

Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12 [PDF]

, 2012
Chemokines and their ligands play a critical role in enabling chronic lymphocytic leukaemia (CLL) cells access to protective microenvironmental niches within tissues, ultimately resulting in chemoresistance and relapse: disruption of these signaling ...
McCaig, Alison M., Alison M McCaig, Alison M. Mccaig, Cosimo Emilio, Alison M. Michie, Leach Michael T., Alison M Michie, Emilio Cosimo, Michael T. Leach, McCaig Alison M., Michael T Leach, Michie, Alison M., Michie Alison M., Cosimo, Emilio, Leach, Michael T.   +14 more
core   +1 more source

Dasatinib-induced spleen contraction leads to transient lymphocytosis [PDF]

, 2023
The tyrosine kinase inhibitor dasatinib is approved for Philadelphia chromosome–positive leukemia, including chronic myeloid leukemia (CML). Although effective and well tolerated, patients typically exhibit a transient lymphocytosis after dasatinib ...
Marcos Jiménez, Ana, Ana Marcos-Jiménez, Daniela Claudino Carvoeiro, Carvoeiro, Daniela Claudino, Valle Gómez-García de Soria, Jens V. Stein, Stein, Jens V., Roy-Vallejo, Emilia, Gómez García de Soria, María del Valle, Abad Santos, Francisco, Ruef, Nora, Zubiaur Precioso, Pablo, Villapalos-García, Gonzalo, Gonzalo Villapalos-García, Lourdes del Campo, Campo, Lourdes del, Muñoz Calleja, Cecilia, Laganá, Claudio, Carlos Cuesta-Mateos, Nora Ruef, Cuesta-Mateos, Carlos, Cecilia Muñoz-Calleja, Emilia Roy-Vallejo, Francisco Abad-Santos, Pablo Zubiaur, Claudio Laganá   +25 more
core   +1 more source

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival [PDF]

, 2012
Recent evidence suggests CML stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated patients. We investigated whether CML stem cells, in a transgenic mouse model of CML-like disease or derived from ...
Allan, Elaine K., Mueller-Tidow, Carsten, Nicolini, Franck E., Bhatia, Ravi, Brunton, Valerie G, Myssina, Svetlana, Hamilton, Ashley, Mysina, Svetlana, Müller-Tidow, Carsten, Koschmieder, Steffen, Allan, Elaine K, Helgason, G. Vignir, Helgason, G Vignir, Brunton, Valerie G., Schemionek, Mirle, Zhang, Bin, Holyoake, Tessa L., Holyoake, Tessa L, Nicolini, Franck E   +18 more
core   +1 more source

MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia. [PDF]

PLoS ONE, 2013
Dasatinib (BMS-354825) is a FDA-approved multitargeted kinase inhibitor of BCR/ABL and Src kinases. It is now used in the treatment of chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapies, including imatinib.
Yanfen Fang, Like Zhong, Meihua Lin, Xinglu Zhou, Hui Jing, Meidan Ying, Peihua Luo, Bo Yang, Qiaojun He   +8 more
doaj   +1 more source

Change of right ventricular systolic pressure can indicate dasatinib‐induced pulmonary arterial hypertension in chronic myeloid leukemia

Cancer Medicine, 2021
Background We investigated the feasibility of the clinical application of non‐invasive transthoracic echocardiography for diagnosis of pulmonary arterial hypertension induced by dasatinib (D‐PAH) in chronic myeloid leukemia (CML).
Sung‐Eun Lee, Jee Hyun Kong, Soo‐Hyun Kim, Eun‐Jung Jang, Nack‐Gyun Chung, Bin Cho, Suk Joong Oh, Hae‐Eok Jung, Ho‐Joong Youn, Woo‐Baek Chung, Dong‐Wook Kim   +10 more
doaj   +1 more source

Dasatinib inhibits actin fiber reorganization and promotes endothelial cell permeability through RhoA‐ROCK pathway

Cancer Medicine, 2017
Treatment with dasatinib, a tyrosine kinase inhibitor, is associated with edema, pleural effusion, and pulmonary edema. We investigated the effect of dasatinib on the barrier function of human microvascular endothelial cells‐1 (HMEC‐1) in vitro and in ...
Swapan K. Dasgupta, Anhquyen Le, K. Vinod Vijayan, Perumal Thiagarajan   +3 more
doaj   +1 more source